Current antineoplastic treatments are not sufficient to cure cancer, in part due to lack efficacy and/or selectivity. Further, they often display significant side effects calling for new therapeutic approaches.
The invention consists in the design, realization and administration of peptides that target hexokinase 2 (HK2) specifically in tumors and display antineoplastic activity.
HK2 is glycolytic enzyme that contributes to metabolism, growth and death inhibition of tumor cells. Its expression is associated with poor prognosis and chemotherapeutic/radiation resistance in diverse solid and hematopoietic tumors.

TRL

Lead Optimization/Preclinical

Inventors

Andrea
Rasola

Francesco
Ciscato

Paolo
Bernardi

Download the brochure

  • Therapeutic factors for the treatment of PolyQ diseases

    The polyglutamine (polyQ) diseases are a group of neurodegenerative disorders caused by expanded cytosine-adenine-guanine (CAG) repeats encoding a long polyQ tract in the respective proteins. To date, at least nine polyQ disorders have been described, see bellow for a list.[...]

  • A treatment for fibrotic disease

    Fibrosing diseases are chronic pathologies, with a different genesis, characterized by various types of cellular or extracellular infiltrates determining a progressive destruction of the parenchyma, which is replaced by fibrous tissue, causing progressive damage to organ anatomy. Fibrosing diseases are[...]

  • Novel Regulated Promoter for Gene Therapy

    Neuroinflammation, characterized by microglial cell-activation, plays a major role in the pathogenesis and progression of multiple neurodegenerative diseases, such as Lysosomal Storage Disorders and Alzheimer’s, severe human conditions currently lacking an effective treatment. Ex vivo gene therapy based on genetically[...]

Subscribe to newsletter

Follow the activities promoted by UniSMART Foundation